EBS Emergent BioSolutions Inc
Price (delayed)
$6.93
Market cap
$366.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.17
Enterprise value
$1.16B
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated
Highlights
Emergent BioSolutions's debt has decreased by 4.8% QoQ and by 4.5% YoY
The company's revenue fell by 7% QoQ but it rose by 2.8% YoY
EBS's EPS is up by 7% year-on-year but it is down by 2% since the previous quarter
EBS's equity has dropped by 60% year-on-year and by 42% since the previous quarter
EBS's gross profit is down by 39% since the previous quarter and by 17% year-on-year
Key stats
What are the main financial stats of EBS
Market
Valuations
Earnings
Shares outstanding
52.91M
Market cap
$366.64M
Enterprise value
$1.16B
Price to book (P/B)
0.94
Price to sales (P/S)
0.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.05
Revenue
$1.1B
EBIT
-$488.8M
EBITDA
-$374.8M
Free cash flow
$37.6M
Per share
Balance sheet
Liquidity
EPS
-$11.17
Free cash flow per share
$0.71
Book value per share
$7.37
Revenue per share
$20.95
TBVPS
$18.62
Total assets
$1.51B
Total liabilities
$1.13B
Debt
$862.2M
Equity
$386.3M
Working capital
$34.8M
Debt to equity
2.23
Current ratio
1.06
Quick ratio
0.43
Net debt/EBITDA
-2.11
Margins
Efficiency
Dividend
EBITDA margin
-34%
Gross margin
27.2%
Net margin
-53.3%
Operating margin
-40.8%
Return on assets
-33.4%
Return on equity
-98%
Return on invested capital
-36.4%
Return on capital employed
-54.7%
Return on sales
-44.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EBS stock price
How has the Emergent BioSolutions stock price performed over time
Intraday
0.73%
1 week
-8.45%
1 month
-35.47%
1 year
86.79%
YTD
188.75%
QTD
1.61%
Financial performance
How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.1B
Gross profit
$299.6M
Operating income
-$449.6M
Net income
-$587M
Gross margin
27.2%
Net margin
-53.3%
EBS's gross profit is down by 39% since the previous quarter and by 17% year-on-year
EBS's gross margin is down by 34% QoQ and by 19% YoY
The company's operating margin rose by 19% YoY and by 10% QoQ
EBS's operating income is up by 17% YoY and by 17% from the previous quarter
Growth
What is Emergent BioSolutions's growth rate over time
Valuation
What is Emergent BioSolutions stock price valuation
P/E
N/A
P/B
0.94
P/S
0.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.05
EBS's EPS is up by 7% year-on-year but it is down by 2% since the previous quarter
The price to book (P/B) is 133% higher than the last 4 quarters average of 0.4 but 45% lower than the 5-year quarterly average of 1.7
EBS's equity has dropped by 60% year-on-year and by 42% since the previous quarter
The P/S is 79% below the 5-year quarterly average of 1.6 but 65% above the last 4 quarters average of 0.2
The company's revenue fell by 7% QoQ but it rose by 2.8% YoY
Efficiency
How efficient is Emergent BioSolutions business performance
EBS's return on equity has dropped by 103% year-on-year and by 29% since the previous quarter
The company's return on assets has shrunk by 55% YoY and by 14% QoQ
EBS's ROIC is down by 47% YoY and by 12% QoQ
EBS's ROS is down by 13% since the previous quarter
Dividends
What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EBS.
Financial health
How did Emergent BioSolutions financials performed over time
The total assets is 34% more than the total liabilities
The total assets has contracted by 31% YoY and by 16% from the previous quarter
EBS's quick ratio is down by 22% YoY and by 14% QoQ
Emergent BioSolutions's debt is 123% higher than its equity
The debt to equity has soared by 137% YoY and by 64% QoQ
EBS's equity has dropped by 60% year-on-year and by 42% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.